» Articles » PMID: 35365570

NFATc1 Signaling Drives Chronic ER Stress Responses to Promote NAFLD Progression

Abstract

Objectives: Non-alcoholic fatty liver disease (NAFLD) can persist in the stage of simple hepatic steatosis or progress to steatohepatitis (NASH) with an increased risk for cirrhosis and cancer. We examined the mechanisms controlling the progression to severe NASH in order to develop future treatment strategies for this disease.

Design: NFATc1 activation and regulation was examined in livers from patients with NAFLD, cultured and primary hepatocytes and in transgenic mice with differential hepatocyte-specific expression of the transcription factor ( . and ). Animals were fed with high-fat western diet (WD) alone or in combination with tauroursodeoxycholic acid (TUDCA), a candidate drug for NAFLD treatment. NFATc1-dependent ER stress-responses, NLRP3 inflammasome activation and disease progression were assessed both in vitro and in vivo.

Results: NFATc1 expression was weak in healthy livers but strongly induced in advanced NAFLD stages, where it correlates with liver enzyme values as well as hepatic inflammation and fibrosis. Moreover, high-fat WD increased NFATc1 expression, nuclear localisation and activation to promote NAFLD progression, whereas hepatocyte-specific depletion of the transcription factor can prevent mice from disease acceleration. Mechanistically, NFATc1 drives liver cell damage and inflammation through ER stress sensing and activation of the PERK-CHOP unfolded protein response (UPR). Finally, NFATc1-induced disease progression towards NASH can be blocked by TUDCA administration.

Conclusion: NFATc1 stimulates NAFLD progression through chronic ER stress sensing and subsequent activation of terminal UPR signalling in hepatocytes. Interfering with ER stress-responses, for example, by TUDCA, protects fatty livers from progression towards manifest NASH.

Citing Articles

Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implications.

Hu S, Ai Y, Hu C, Cassim Bawa F, Xu Y Genes Dis. 2025; 12(3):101372.

PMID: 39911797 PMC: 11795806. DOI: 10.1016/j.gendis.2024.101372.


Caveolin-1 mitigates the advancement of metabolic dysfunction-associated steatotic liver disease by reducing endoplasmic reticulum stress and pyroptosis through the restoration of cholesterol homeostasis.

Xu H, Li Y, Guo N, Wu S, Liu C, Gui Z Int J Biol Sci. 2025; 21(2):490-506.

PMID: 39781461 PMC: 11705642. DOI: 10.7150/ijbs.100794.


Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances.

Zhao L, Tang H, Cheng Z Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770566 PMC: 11677259. DOI: 10.3390/ph17121724.


Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer.

Klein L, Tu M, Krebs N, Urbach L, Grimm D, Latif M Nat Commun. 2025; 16(1):335.

PMID: 39762215 PMC: 11704331. DOI: 10.1038/s41467-024-55330-7.


Small molecule-driven LKB1 deacetylation is responsible for the inhibition of hepatic lipid response in NAFLD.

Qin W, Ding Y, Zhang W, Sun L, Weng J, Zheng X J Lipid Res. 2025; 66(2):100740.

PMID: 39755206 PMC: 11808498. DOI: 10.1016/j.jlr.2024.100740.


References
1.
Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

2.
Han C, Rho H, Kim A, Kim T, Jang K, Won Jun D . FXR Inhibits Endoplasmic Reticulum Stress-Induced NLRP3 Inflammasome in Hepatocytes and Ameliorates Liver Injury. Cell Rep. 2018; 24(11):2985-2999. DOI: 10.1016/j.celrep.2018.07.068. View

3.
Chan J, Luzuriaga J, Maxwell E, West P, Bensellam M, Laybutt D . The balance between adaptive and apoptotic unfolded protein responses regulates β-cell death under ER stress conditions through XBP1, CHOP and JNK. Mol Cell Endocrinol. 2015; 413:189-201. DOI: 10.1016/j.mce.2015.06.025. View

4.
Singh S, Chen N, Hessmann E, Siveke J, Lahmann M, Singh G . Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. EMBO J. 2015; 34(4):517-30. PMC: 4331005. DOI: 10.15252/embj.201489574. View

5.
Baumgart S, Chen N, Siveke J, Konig A, Zhang J, Singh S . Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Cancer Discov. 2014; 4(6):688-701. PMC: 4069603. DOI: 10.1158/2159-8290.CD-13-0593. View